On January 30, 2025 Orion Corporation ("Orion"), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, reported that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body platform (Press release, Orion, JAN 30, 2025, View Source [SID1234649972]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreements, Invenra will leverage its B-Body bispecific antibody platform from monoclonal antibody discovery to optimized panels of bispecific leads. Orion will be responsible for the selection of targets and will be solely responsible for the development, manufacturing, and global commercialization of these candidates. The agreement provides Orion with commercial licenses for up to two bispecific antibodies.
"This collaboration highlights the strength and versatility of our B-Body platform in addressing complex biological challenges," said Roland Green, CEO of Invenra. "We are thrilled to work with Orion, a company that shares our commitment to delivering innovative therapies that address critical unmet medical needs."
"Partnering with Invenra represents an important step in Orion’s strategy to expand our portfolio in the bispecific antibody space," said Antti Haapalinna, Vice President, Head of External Science & Partnering R&D, Orion. "Invenra’s cutting-edge bispecific discovery platform, combined with Orion’s expertise in development and commercialization, will accelerate the creation of impactful new therapies for patients worldwide."
This discovery collaboration combines Invenra’s advanced engineering expertise in bispecific antibody discovery with Orion’s established track record in pharmaceutical innovation, setting the stage for the development of next-generation therapeutic solutions.